On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of rak pluća conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes tumor cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb je otkrio da je tvrtka podnijela Opdivoov zahtjev za liječenje indikacija raka pluća FDA-i i farmaceutskoj upravi EU-a. Naravno, ambiciozna tvrtka Squibb neće se zadovoljiti samo rakom pluća i melanomom. Zapravo, Squibb trenutačno provodi više od 35 studija samo Opdiva ili u kombinaciji s drugim lijekovima za liječenje različitih vrsta tumora. Prema analitičarima, buduća prodaja Opdiva doseći će čak 5 milijardi američkih dolara.
Rak imunoterapija research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Detaljno izvješće na engleskom jeziku:
Bristol-Myers Squibb ($ BMY) izvanredan imuno-onkološki lijek nivolumab, odobren prošli mjesec kao Opdivo, postigao je izvanredan uspjeh u ispitivanju kasnog stadija raka pluća, podupirući očekivanja prodaje za pionirski tretman.
U studiji na 272 pacijenta u kojoj je Opdivo suprotstavljen standardnom lijeku protiv raka docetakselu, Bristol-Myersov lijek pokazao je tako superiorno ukupno preživljenje u usporedbi s kontrolnom grupom da je postigao svoju primarnu krajnju točku prije planiranog roka, što je dovelo do preporuke odbora za praćenje podataka ispitivanja studiju rano prekinuti. Bristol-Myers sada poziva pacijente u skupini koja je primala docetaksel da se odluče za Opdivo kroz otvoreno proširenje studije.
Liječenje Bristol-Myers je osmišljeno da potakne napad imunološkog sustava na tumore blokiranjem puta zvanog PD-1, koji, ako se ne kontrolira, omogućuje stanicama raka da prođu neotkrivene od strane prirodne obrane tijela. Kao i Merckova ($ MRK) slična Keytruda, Opdivo je prošle godine dobio odobrenje FDA za liječenje melanoma, ali Bristol-Myersov lijek stoji sam za rak pluća, budući da njegov najnoviji klinički uspjeh označava prvi put da je inhibitor PD-1 ucrtao prednost preživljavanja protiv bolesti, rekla je tvrtka.
Opdivo’s particular promise in karcinom pluća nedrobnih stanica has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers je podnio zahtjeve protiv raka pluća u SAD-u i Europi za Opdivo u liječenju raka pluća, očekujući da će kasnije ove godine proširiti upotrebu lijeka.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, karcinom glave i vrata, glioblastoma, Non-Hodgkin lymphoma and other cancers.
